See more : Godrej Consumer Products Limited (GODREJCP.NS) Income Statement Analysis – Financial Results
Complete financial analysis of TRxADE HEALTH, Inc. (MEDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TRxADE HEALTH, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
You may be interested
- byNordic Acquisition Corporation (BYNOU) Income Statement Analysis – Financial Results
- Jaguar Global Growth Corporation I (JGGCU) Income Statement Analysis – Financial Results
- Beyond Air, Inc. (XAIR) Income Statement Analysis – Financial Results
- VisasQ Inc. (4490.T) Income Statement Analysis – Financial Results
- Felissimo Corporation (3396.T) Income Statement Analysis – Financial Results
TRxADE HEALTH, Inc. (MEDS)
About TRxADE HEALTH, Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.27M | 11.45M | 9.89M | 17.12M | 7.44M | 3.83M | 2.93M | 2.48M | 4.99M | 1.50M | 955.88K | 806.05K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.67M | 6.00M | 5.14M | 11.42M | 2.57M | 449.05K | 0.00 | 16.36K | 1.93M | 440.05K | 944.07K | 689.81K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.60M | 5.45M | 4.75M | 5.71M | 4.87M | 3.38M | 2.93M | 2.47M | 3.06M | 1.06M | 11.81K | 116.24K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 31.41% | 47.62% | 47.99% | 33.33% | 65.50% | 88.28% | 100.00% | 99.34% | 61.38% | 70.59% | 1.24% | 14.42% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.38M | 1.16M | 1.37M | 662.73K | 647.14K | 949.95K | 375.17K | 286.76K | 319.44K | 319.44K | 611.71K | 198.41K | 0.00 | 0.00 | 3.57K |
| General & Administrative | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.30M | 3.70M | 2.11M | 2.10M | 266.95K | 28.50M | 0.00 | 5.16K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.63K | 355.12K | 374.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 24.77K | 5.16K |
| Other Expenses | 14.54K | 1.60M | -1.23M | 3.25M | 72.08K | 161.64K | 67.50K | 131.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.42K | 0.00 |
| Operating Expenses | 9.86M | 8.21M | 8.81M | 7.49M | 4.38M | 3.30M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 28.19K | 8.73K |
| Cost & Expenses | 15.54M | 14.20M | 13.96M | 18.90M | 6.94M | 3.75M | 2.27M | 3.47M | 5.98M | 2.93M | 3.04M | 956.76K | 28.50M | 28.19K | 8.73K |
| Interest Income | 4.20K | 20.99K | 23.59K | 29.39K | 53.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.20M | 336.21K | 23.59K | 29.39K | 53.23K | 57.54K | 157.06K | 151.50K | 130.14K | 4.15K | 7.28K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.05M | 194.70K | 138.91K | 102.52K | 94.73K | 87.62K | -395.10K | 8.67K | 3.80K | 4.80K | 3.99K | 2.63K | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.72M | -1.85M | -5.15M | -2.51M | 660.55K | 96.65K | 288.98K | -984.03K | -133.27K | -2.00M | -2.08M | -148.09K | -28.50M | -28.19K | -8.73K |
| EBITDA Ratio | -74.89% | -22.18% | -52.11% | -9.80% | 8.88% | 6.36% | 24.92% | -39.65% | -19.70% | -95.35% | -217.60% | -18.37% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.26M | -2.76M | -5.29M | -1.78M | 565.82K | -87.62K | 395.10K | -984.03K | -987.05K | -1.43M | -2.08M | -150.71K | -28.50M | -28.19K | -8.73K |
| Operating Income Ratio | -87.80% | -24.08% | -53.51% | -10.40% | 7.61% | -2.29% | 13.48% | -39.65% | -19.77% | -95.67% | -218.02% | -18.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.46M | -362.72K | -23.59K | -29.39K | -778.17K | 96.65K | -106.11K | -165.83K | -119.51K | -580.57K | -7.28K | 0.00 | 28.47M | 0.00 | 0.00 |
| Income Before Tax | -13.72M | -3.91M | -5.32M | -2.54M | -284.43K | 9.04K | 288.98K | -1.17M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50K | 0.00 | 0.00 |
| Income Before Tax Ratio | -165.86% | -34.15% | -53.75% | -14.81% | -3.82% | 0.24% | 9.86% | -47.27% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.34M | 400.34K | -1.20M | 29.39K | 125.30K | -154.20K | -50.94K | 1.62M | 130.14K | 576.42K | 7.28K | 0.00 | 28.50M | 28.19K | 8.73K |
| Net Income | -17.84M | -4.31M | -4.11M | -2.57M | -409.73K | 9.04K | 288.98K | -2.76M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50M | -28.19K | -8.73K |
| Net Income Ratio | -215.70% | -37.65% | -41.59% | -14.98% | -5.51% | 0.24% | 9.86% | -111.21% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
| EPS | -23.35 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.89 | -3.20 | -6.30 | -13.50 | -0.97 | -273.59 | -0.27 | -0.11 |
| EPS Diluted | -7.49 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.87 | -3.20 | -6.07 | -13.35 | -0.97 | -269.45 | -0.27 | -0.11 |
| Weighted Avg Shares Out | 764.06K | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 355.06K | 349.64K | 349.64K | 319.37K | 154.91K | 154.91K | 104.16K | 105.76K | 81.20K |
| Weighted Avg Shares Out (Dil) | 2.38M | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 378.74K | 350.50K | 349.64K | 331.46K | 156.69K | 154.91K | 105.76K | 105.76K | 81.20K |
TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.
TAMPA, FL, Oct. 17, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of pharmaceutical business-to-business exchange platform, which recently merged with Superlatus, Inc. (“Superlatus”), today reconfirms its commitment to pharmaceutical marketplace via its subsidiary Trxade,...
Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales
TAMPA, FL, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. (“Superlatus”), a food technology and distribution company and wholly owned subsidiary of TRxADE HEALTH, Inc. (NASDAQ: MEDS, “TRxADE”), a pharmaceutical exchange platform provider, is pleased to announce that its subsidiary, Superlatus...
Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.
TAMPA, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. (“Superlatus”), wholly owned subsidary of TRxADE HEALTH, Inc. (NASDAQ: MEDS), a pharmaceutical exchange platform provider, entered into an all-cash asset purchase agreement to acquire the assets of Spero Foods, Inc....
TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.
NEW YORK, NY / ACCESSWIRE / September 7, 2023 / TRxADE Health, Inc. (NASDAQ:MEDS), known for its pharmaceutical exchange platform, has recently merged with Superlatus, Inc., a leading food technology and distribution company. The combined entity has now announced a...
TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market
NEW YORK, NY / ACCESSWIRE / September 6, 2023 / TRxADE Health, Inc. (NASDAQ:MEDS), known for its pharmaceutical exchange platform, has recently merged with Superlatus, Inc., a leading food technology and distribution company. The combined entity has now announced a...
Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand
TAMPA, FL, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Superlatus Inc. ('Superlatus' or the 'Company') recently merged with TRxADE HEALTH, Inc. (NASDAQ: MEDS) and is gearing up to revolutionize the snack industry. The Company has unveiled its intent to introduce pulse-based...
Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.
TAMPA, FL, Aug. 22, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (NASDAQ: MEDS), a pharmaceutical exchange platform provider that recently merged with food technology and distribution company Superlatus, Inc., today entered into a binding agreement to acquire The Urgent Company,...
TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing
TAMPA, FL, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (NASDAQ: MEDS) (“TRxADE”), a pharmaceutical exchange platform provider, today announced that it has filed for an extension to file its Quarterly Report on Form 10-Q for Q2 pursuant to...
Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team
TAMPA, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc (NASDAQ: MEDS), parent company of pharmaceutical B2B exchange platform, which recently merged with Superlatus, Inc today announced the appointments of Forbes Fisher as Chief Operating Officer and Dr. Eugenio...
TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.
TAMPA, FL / ACCESSWIRE / July 31, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will...
Source: https://incomestatements.info
Category: Stock Reports